Cited by 952Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Open access

Reck, Martin, Kaiser, Rolf, Mellemgaard, Anders, Douillard, Jean-Yves, Orlov, Sergey, Krzakowski, Maciej, von Pawel, Joachim, Gottfried, Maya, Bondarenko, Igor, Liao, Meilin, Gann, Claudia-Nanette, Barrueco, José, Gaschler-Markefski, Birgit, Novello, Silvia·2014·The Lancet Oncology

DOI 10.1016/s1470-2045(13)70586-2

Open this paper in CoChat — free account Open PDF

Abstract

Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70586-2

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178

Show all 36 references

Research works printed but not linked: 2

Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01

Sorted by citations

Items 201–300 of 952

Tumor microenvironment in lung cancer-derived brain metastasis
Liu, W., Powell, C. A., & Wang, Q. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002127 · Cited by 49
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations – Still a daily challenge
Su, C., Zhou, F., Shen, J., Zhao, J., & O'Brien, M. E. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.002 · Cited by 44
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Quintela-Fandiño, M., Lluch, A. M., Manso, L., Calvo, I., Cortés, J., García-Sáenz, J. Á., Gil‐Gil, M., Martínez-Jáñez, N., González-Martı́n, A., Adrover, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0738 · Cited by 43
Targeting the PD-1/PD-L1 axis in non–small cell lung cancer
Kumar, R., Collins, D. C., Dolly, S. O., McDonald, F., O'Brien, M. E. R., & Yap, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.002 · Cited by 45
Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
Soldera, S. V., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00050 · Cited by 44
Update in Lung Cancer 2014
Spira, A. E., Halmos, B., & Powell, C. A. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0756up · Cited by 44
Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
Watanabe, N., Niho, S., Kirita, K., Umemura, S., Matsumoto, S., Yoh, K., Ohmatsu, H., & Goto, K. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2775-y · Cited by 42
The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
Grześk, G., Woźniak-Wiśniewska, A., Błażejewski, J., Górny, B., Wołowiec, Ł., Rogowicz, D., & Nowaczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010282 · Cited by 43
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model
Bill, R., Fagiani, E., Zumsteg, A., Antoniadis, H., Johansson, D., Haefliger, S., Albrecht, I., Hilberg, F., & Christofori, G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3036 · Cited by 42
Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer ( W est J apan O ncology G roup 5910L): An open‐label, randomized, phase 2 trial
Takeda, M., Yamanaka, T., Seto, T., Hayashi, H., Azuma, K., Okada, M., Sugawara, S., Daga, H., Hirashima, T., Yonesaka, K., et al. (2016) · Cancer · doi:10.1002/cncr.29893 · Cited by 44
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Kubota, K., Yoshioka, H., Oshita, F., Hida, T., Yoh, K., Hayashi, H., Kato, T., Kaneda, H., Yamada, K., Tanaka, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7297 · Cited by 42
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
Corral, J., Majem, M., Rodríguez‐Abreu, D., Carcereny, E., Cortes, A. A., Llorente, M. D. M., López-Picazo, J. M., García, Y. G., Dómine, M., & Criado, M. P. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02053-7 · Cited by 42
Antiangiogeneic Strategies in Mesothelioma
Nowak, A. K., Brosseau, S., Cook, A., & Zalcman, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00126 · Cited by 42
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 42
Self-citation
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
Zhou, Z., Liu, Z., Ou, Q., Wu, X., Wang, X., Shao, Y. W., Liu, H., & Yu, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0120 · Cited by 42
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0367-8 · Cited by 41
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer
Digumarti, R., Bapsy, P. P., Suresh, A. V., Bhattacharyya, G. S., Dasappa, L., Shan, J. S., & Gerber, D. E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.010 · Cited by 41
Addressing the unmet need in lung cancer: The potential of immuno-oncology
Scagliotti, G. V., Bironzo, P., & Vansteenkiste, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.001 · Cited by 41
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
Cutsem, E. V., Prenen, H., D’Haens, G., Bennouna, J., Carrato, A., Ducreux, M. P., Bouché, O., Sobrero, A. F., Latini, L., Staines, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv286 · Cited by 41
Cationically Modified Inhalable Nintedanib Niosomes: Enhancing Therapeutic Activity Against Non-Small-Cell Lung Cancer
Shukla, S. K., Nguyen, V., Goyal, M., & Gupta, V. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0045 · Cited by 42
Current Issues in Malignant Pleural Mesothelioma Evaluation and Management
Ai, J., & Stevenson, J. P. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0122 · Cited by 40
The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model
Feng, J., & Qin, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s159935 · Cited by 40
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 42
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus
Τzouvelekis, Α., Antoniou, K. M., Kreuter, M., Evison, M., Blum, T. G., Poletti, V. E., Grigoriu, B. D., Vancheri, C., Spagnolo, P., Karampitsakos, Τ., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00529-2020 · Cited by 39
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Zer, A., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00329 · Cited by 39
Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis
Cheng, S., Qureshi, M. I., Pullenayegum, E., Haynes, A. E., & Chan, K. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000225 · Cited by 39
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 40
Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases
Haas, G., Fan, S., Ghadimi, M. B., Oliveira, T. D., & Conradi, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.612774 · Cited by 39
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40
PI3K at the crossroads of tumor angiogenesis signaling pathways
Soler, A., Angulo‐Urarte, A., & Graupera, M. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.975624 · Cited by 39
Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma
Ikemori, R., Gabasa, M., Duch, P., Vizoso, M., Bragado, P., Arshakyan, M., Luis, I.-C., Marín, A., Morán, S., de Moura, M. C., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0637 · Cited by 39
Update on systemic therapy of advanced non-small-cell lung cancer
Čufer, T., & Knez, L. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940327 · Cited by 37
Targeting Angiogenesis in Colorectal Cancer
Kircher, S. M., Nimeiri, H. S., & Benson, A. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000192 · Cited by 37
Therapeutic and pathological roles of fibroblast growth factors in pulmonary diseases
Agha, E. E., Seeger, W., & Bellusci, S. (2016) · Developmental Dynamics · doi:10.1002/dvdy.24468 · Cited by 39
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
Schmid, U., Döge, C., Dallinger, C., & Freiwald, M. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.11.004 · Cited by 38
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
O'Brien, M. E. R., Gaafar, R. M., Hasan, B., Menis, J., Čufer, T., Popat, S., Woll, P. J., Surmont, V. F. M., Georgoulias, V., Montes, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.026 · Cited by 37
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
Eisen, T. G., Loembé, A., Shparyk, Y. V., MacLeod, N. J., Jones, R. J., Mazurkiewicz, M., Temple, G., Dressler, H., & Bondarenko, I. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.313 · Cited by 36
Self-citation
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Lazzari, C., Bulotta, A., Ducceschi, M., Viganò, M. G., Brioschi, E., Corti, F., Gianni, L., & Gregorc, V. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00004 · Cited by 37
The emerging treatment landscape of advanced non-small cell lung cancer
Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36
Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer
Okamoto, I., Miyazaki, M., Takeda, M., Terashima, M., Azuma, K., Hayashi, H., Kaneda, H., Kurata, T., Tsurutani, J., Seto, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000395 · Cited by 35
Self-citation
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
Hibi, M., Kaneda, H., Tanizaki, J., Sakai, K., Togashi, Y., Terashima, M., Velasco, M. A. D., Fujita, Y., Banno, E., Nakamura, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.13071 · Cited by 35
Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
Yamakawa, H., Oba, T., Ohta, H., Tsukahara, Y., Kida, G., Tsumiyama, E., Nishizawa, T., Kawabe, R., Sato, S., Akasaka, K., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0920-9 · Cited by 35
A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis
Song, M. J., Kim, S. Y., Park, M. S., Kang, M. J., Lee, S. H., & Park, S. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-82182-8 · Cited by 35
The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab
Kwok, H. F., Zhang, S., McCrudden, C. M., Chen, M., & Lin, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s80518 · Cited by 34
Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Popat, S., Mellemgaard, A., Fahrbach, K. R., Martin, A. L., Rizzo, M., Kaiser, R., Griebsch, I., & Reck, M. (2014) · Future Oncology · doi:10.2217/fon.14.290 · Cited by 34
Self-citation
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
Perdrizet, K., & Leighl, N. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0617-6 · Cited by 36
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis
Vickers, A. D., Winfree, K. B., Carter, G. C., Kiiskinen, U., Jen, M., Stull, D. E., Kaye, J. A., & Carbone, D. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5569-5 · Cited by 34
Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
Cheng, Y., Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., He, J., Shi, Y., Chen, W., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2913 · Cited by 34
A phase II study of nintedanib in patients with relapsed small cell lung cancer
Han, J., Kim, H. Y., Lim, K. Y., Hwangbo, B., & Lee, J. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.002 · Cited by 34
Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
Lim, J. S. J., & Soo, R. A. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816661091 · Cited by 33
Biomimetic Nanoplatform for Dual‐Targeted Clearance of Activated and Senescent Cancer‐Associated Fibroblasts to Improve Radiation Resistance in Breast Cancer
Jian, C., Wu, T., Wang, L., Gao, C., Fu, Z., Zhang, Q., & Shi, C. (2024) · Small · doi:10.1002/smll.202309279 · Cited by 33
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
Quintela-Fandiño, M., Urruticoechea, A., Guerra, J. A., Gil, M., González-Martı́n, A., Márquez, R. M., Hernández-Agudo, E., Rodríguez-Martín, C., Gil-Martín, M., Bratos, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.397 · Cited by 33
Overall survival in non-small cell lung cancer-what is clinically meaningful?
Fenchel, K., Sellmann, L., & Dempke, W. C. M. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.06 · Cited by 33
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 35
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
László, V., Valkó, Z., Kovács, I., Ozsvar, J., Hoda, M. A., Klikovits, T., Lakatos, D., Czirók, A., Garay, T., Stiglbauer, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1507 · Cited by 33
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study
Visser, S., Huisbrink, J., Veer, N. E. V. ‘., van Toor, J. J., van Boxem, A. J. M., van Walree, N. C., Stricker, B. H. C., & Aerts, J. G. J. V. (2018) · European Respiratory Journal · doi:10.1183/13993003.00884-2018 · Cited by 33
Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202
Korprasertthaworn, P., Chau, N., Nair, P. C., Rowland, A., & Miners, J. O. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.08.018 · Cited by 33
Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma
Kreus, M., Lehtonen, S. T., Skarp, S., & Kaarteenaho, R. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250109 · Cited by 33
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, A., Crabb, S. J., Huddart, R. A., Vasudev, N. S., Birtle, A. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00158-9 · Cited by 33
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape
Mühlenberg, T., Falkenhorst, J., Schulz, T., Fletcher, B. S., Teuber, A., Krzeciesa, D., Klooster, I., Lundberg, M. Z., Wilson, L., Lategahn, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01197 · Cited by 32
Nintedanib in non-small cell lung cancer: from preclinical to approval
Caglevic, C., Grassi, M., Raez, L. E., Listì, A., Giallombardo, M., Bustamante, E. I., Bazo, I. G., & Rolfo, C. D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815579608 · Cited by 32
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV
Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Tufman, A., Hoffknecht, P., Ulm, B., et al. (2020) · Clinical Medicine Insights Oncology · doi:10.1177/1179554920951358 · Cited by 33
Self-citation
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Stenzinger, A., Tufman, A., Hoffknecht, P., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-197 · Cited by 32
Self-citation
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer
Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4180 · Cited by 31
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Kendra, K. L., Plummer, R., Salgia, R., O'Brien, M. E. R., Paul, E. M., Suttle, A. B., Compton, N., Xu, C., Ottesen, L. H., & Villalona-Calero, M. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0431 · Cited by 31
Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
Shiratori, T., Tanaka, H., Tabe, C., Tsuchiya, J., Ishioka, Y., Itoga, M., Taima, K., Takanashi, S., & Tasaka, S. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13437 · Cited by 31
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33
High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis
Kou, W., Li, B., Shi, Y., Zhao, Y., Yu, Q., Zhuang, J., Xu, Y., & Peng, W. (2022) · BMC Cancer · doi:10.1186/s12885-021-08912-3 · Cited by 30
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 32
Self-citation
Nintedanib in ovarian cancer
Khalique, S., & Banerjee, S. N. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1353599 · Cited by 31
Hypertension in cancer patients treated with anti-angiogenic based regimens
Wasserstrum, Y., Kornowski, R., Raanani, P., Leader, A., Pasvolsky, O., & Iakobishvili, Z. (2015) · Cardio-Oncology · doi:10.1186/s40959-015-0009-4 · Cited by 30
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
Gottfried, M., Bennouna, J., Bondarenko, I., Douillard, J., Heigener, D. F., Krzakowski, M. J., Mellemgaard, A., Novello, S., Орлов, С. В., Summers, Y., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0517-2 · Cited by 30
Self-citation
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
Rihawi, K., Gelsomino, F., Sperandi, F., Melotti, B., Fiorentino, M., Casolari, L., & Ardizzoni, A. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817725486 · Cited by 30
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
Quintela-Fandiño, M., Apala, J. V., Malón, D., Mouron, S. A., Hornedo, J., González‐Cortijo, L., Colomer, R., & Guerra, J. A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1152-x · Cited by 29
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
Joshi, A., Mishra, R., Desai, S., Chandrani, P., Kore, H., Sunder, R., Hait, S., Iyer, P. S., Trivedi, V., Choughule, A. B., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27905 · Cited by 30
Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
Tabchi, S., & Blais, N. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00052 · Cited by 29
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
Marzin, K., Kretschmar, G., Luedtke, D., Kraemer, S., Kuelzer, R., Schlenker‐Herceg, R., Schmid, U., Schnell, D., & Dallinger, C. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1025 · Cited by 28
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Reck, M., Garassino, M. C., Imbimbo, M., Shepherd, F. A., Socinski, M. A., Shih, J., Tsao, A. S., Lee, P., Winfree, K. B., Sashegyi, A. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.025 · Cited by 29
Self-citation
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
Kotsakis, A. P., Matikas, A., Koinis, F., Kentepozidis, N. K., Varthalitis, I. I., Karavassilis, V., Samantas, E., Katsaounis, P., Dermitzaki, E. K., Hatzidaki, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.281 · Cited by 28
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer
Lü, S., Chang, J., Liu, X., Shi, J., Lü, Y., Li, W., Yang, J., Zhou, J., Wang, J., An, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7145 · Cited by 29
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 29
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Pirker, R., & Filipits, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9612-6 · Cited by 28
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
Reck, M., Mellemgaard, A., von Pawel, J., Gottfried, M., Bondarenko, I., Cheng, Y., Zarogoulidis, K., Luft, A. V., Bennouna, J., Barrueco, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.003 · Cited by 28
Self-citation
Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients
Prasad, K. T., Kaur, H., Muthu, V., Aggarwal, A. N., Behera, D., & Singh, N. (2018) · World Journal of Clinical Oncology · doi:10.5306/wjco.v9.i7.140 · Cited by 27
Different treatment efficacies and side effects of cytotoxic chemotherapy
Li, L.-J., Chong, Q.-Y., Wang, L., Cher, G. B., & Soo, R. A. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.63 · Cited by 27
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer
Suzuki, J., Tsuboi, M., & Ishii, G. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2019018 · Cited by 22
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
Yen, C.-J., Kim, T., Feng, Y., Chao, Y., Lin, D., Ryoo, B., Huang, D., Schnell, D., Hocke, J., Loembé, A., et al. (2018) · Liver Cancer · doi:10.1159/000486460 · Cited by 27
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis
Feng, S., Wang, G., Zhang, J., Xie, Y., Sun, R., Fei, F., Huang, J., Wang, Y., Aa, J., & Zhou, F. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.16 · Cited by 27
Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
Tang, J. P., Li, X. Y., Liang, J., Wu, D. P., Peng, L. H., & Li, X. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15288447760357 · Cited by 27
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Targeting FGFR in Squamous Cell Carcinoma of the Lung
Hashemi‐Sadraei, N., & Hanna, N. H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0513-6 · Cited by 26
Assessment of the risk of antiangiogenic agents before and after surgery
Bailey, C. E., & Parikh, A. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.002 · Cited by 26
Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitor Therapy: Insights from VARGADO, A Prospective Study in Patients with Lung Adenocarcinoma
Grohé, C., Gleiber, W., Haas, S., Losem, C. J., Mueller-Huesmann, H., Schulze, M., Franke, C., Basara, N., Atz, J., & Kaiser, R. (2019) · Future Oncology · doi:10.2217/fon-2019-0262 · Cited by 26
Self-citation
Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Sofias, A. M., Lorenzi, F. D., Peña, Q., Shalmani, A. A., Vucur, M., Wang, J., Kiessling, F. M., Shi, Y., Consolino, L., Storm, G., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113831 · Cited by 28
Antiangiogenic Therapy in Advanced Non–small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials
Raphael, J., Chan, K., Karim, S., Kerbel, R. S., Lam, H., Santos, K. D., Saluja, R., & Verma, S. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.004 · Cited by 26
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Forster, M. D., Hackshaw, A. K., Pas, T. M. D., Cobo, M., Garrido, P., Summers, Y., Dingemans, A. C., Flynn, M., Schnell, D., von Wangenheim, U., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.007 · Cited by 26
Self-citation
Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells
Kovalchuk, B., Berghoff, A. S., Karreman, M. A., Frey, K., Piechutta, M., Fischer, M. D., Grosch, J. K., Heiland, S., Breckwoldt, M. O., Hilberg, F., et al. (2020) · Clinical & Experimental Metastasis · doi:10.1007/s10585-020-10055-x · Cited by 27
EGFR tyrosine kinase inhibitorsversuschemotherapy inEGFRwild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Tomasini, P., Brosseau, S., Mazières, J., Merlio, J., Beau‐Faller, M., Mosser, J., Wislez, M., Ouafik, L., Besse, B., Rouquette, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00514-2017 · Cited by 27

Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M. J., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba8011 · Cited by 32
Self-citation
MA14.06 Nintedanib-Docetaxel in 2nd Line Treatment in No Squamous Non-Small Cell Lung Cancer Patients, Refractory to First Line Treatment (GFPC02-15)
Auliac, J. B., Monnet, I., Bizieux, A., Greillier, L., Falchero, L., Robinet, G., Lamy, R., Hauss, P.-A., Guisier, F., Léna, H., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.614
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Hanna, N. H., Kaiser, R., Sullivan, R. N., Aren, O. R., Ahn, M., Tiangco, B., Voccia, I., von Pawel, J., Kovčin, V., Agulnik, J. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.011 · Cited by 88
Self-citation
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
Ljubičić, L., Janžič, U., Unk, M., Terglav, A. S., Mohorčič, K., Seiwerth, F., Bitar, L., Badovinac, S., Pleština, S., Koršić, M., et al. (2023) · Radiology and Oncology · doi:10.2478/raon-2023-0040 · Cited by 7
Prior Taxane Use in the Lume-Lung 1 Phase III Trial and the Effect on Outcome Following 2Nd-Line Treatment with Nintedanib (Bibf 1120) and Docetaxel in Patients with Advanced Nsclc
Krzakowski, M. J., Mellemgaard, A., Orlov, S., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Barrueco, J., Gaschler‐Markefski, B., Kaiser, R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.33 · Cited by 3
Self-citation

See all

Authors: Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
Affiliations: German Center for Lung Research (DE)
Boehringer Ingelheim (Germany) (DE)
Herlev Hospital (DK)
The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Meir Medical Center (IL)
Dnipro State Medical University (UA)
Shanghai Jiao Tong University (CN)
Boehringer Ingelheim (United States) (US)
University of Turin (IT)
ORCID: Reck, Martin
Kaiser, Rolf
Mellemgaard, Anders
Douillard, Jean-Yves
Krzakowski, Maciej
Bondarenko, Igor
Novello, Silvia
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2014-02
Volume: 15
Issue: 2
Pages: 143-155
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(13)70586-2
OpenAlex: W2170030318
Cited by: 951
References: 36
Citations by year: 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
FWCI: 98.24
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
MeSH terms: Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks